Literature DB >> 9549920

Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders.

P J Lúcio1, M T Faria, A M Pinto, M R da Silva, M E Correia Júnior, R J da Costa, A B Parreira.   

Abstract

BACKGROUND AND
OBJECTIVE: Abnormalities in the expression of cell adhesion molecules (CAM) are thought to influence the patterns of intranodal growth and hematogeneous spread of malignant cells in chronic lymphoproliferative disorders (LPD). Therefore, the characterization of CAM phenotypic profiles of the neoplastic clones in LPD may help to identify distinct subtypes with prognostic implications. In this work we sought to investigate whether the expression of CAM by circulating malignant cells in patients with B-cell LPD differed from that of normal peripheral blood B-lymphocytes (PBL) and whether the observed phenotypic patterns could be correlated to other biological and clinical parameters of known clinical relevance. DESIGN AND METHODS: Peripheral blood mononuclear cells were obtained from 148 patients with B-cell chronic lymphocytic leukemia (B-CLL), 52 with B-cell non-Hodgkin lymphomas (NHL) and 10 with hairy cell leukemia (HCL). The expression of CAM was analyzed by flow cytometry using monoclonal antibodies against CD49d, CD29, CD11a, CD11b, CD11c, CD18, CD62L, CD54 and CD44.
RESULTS: All CAM were detected in normal peripheral blood B-lymphocytes, except CD11c and CD54, which were present in only a minority of cells. Fluorescence mean channel values (FMC) showed that all molecules, with the exception of CD44, were expressed with dim intensity. Emerging patterns of CAM expression, as assessed by FMC values, were observed in different LPD: thus, B-CLL is characterized by a very low expression of CD49d/CD29 and beta 2 integrins. In this disorder, CD49d/CD29, CD11a, and CD54 increase with tumor burden; NHL show high expression of CD29 and CD54; strong expression of all molecules (except CD11a) was found in HCL, particularly CD11c (FMC values 60 times higher than normal). CD62L was faintly expressed in all diagnostic groups, whereas CD11c showed consistently high FMC values. INTERPRETATION AND
CONCLUSIONS: The data shows that the phenotypic characterization of LPD can be further refined by the analysis of their patterns of CAM expression which may help to identify distinct subsets within each nosological group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9549920

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  10 in total

1.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

2.  Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.

Authors:  Lynn R Goldin; Mary L McMaster; Melissa Rotunno; Sarah E M Herman; Kristine Jones; Bin Zhu; Joseph Boland; Laurie Burdett; Belynda Hicks; Sarangan Ravichandran; Brian T Luke; Meredith Yeager; Laura Fontaine; Alisa M Goldstein; Stephen J Chanock; Margaret A Tucker; Adrian Wiestner; Gerald Marti; Neil E Caporaso
Journal:  Blood       Date:  2016-09-14       Impact factor: 22.113

3.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

4.  Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.

Authors:  A Tzankov; A-C Pehrs; A Zimpfer; S Ascani; A Lugli; S Pileri; S Dirnhofer
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

5.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

6.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Authors:  Pietro Bulian; Tait D Shanafelt; Chris Fegan; Antonella Zucchetto; Lilla Cro; Holger Nückel; Luca Baldini; Antonina V Kurtova; Alessandra Ferrajoli; Jan A Burger; Gianluca Gaidano; Giovanni Del Poeta; Chris Pepper; Davide Rossi; Valter Gattei
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

Review 7.  Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.

Authors:  Heidi Harjunpää; Marc Llort Asens; Carla Guenther; Susanna C Fagerholm
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

8.  Genetic variation is the major determinant of individual differences in leukocyte endothelial adhesion.

Authors:  Michael A Grassi; Vidhya Rao; Kathryn P Winkler; Wei Zhang; Joseph D Bogaard; Siquan Chen; Bonnie LaCroix; Divya Lenkala; Jalees Rehman; Asrar B Malik; Nancy J Cox; R Stephanie Huang
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

Review 9.  Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.

Authors:  Francesco Autore; Paolo Strati; Luca Laurenti; Alessandra Ferrajoli
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

10.  Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.

Authors:  Qin Yang; Kaihu Li; Xin Li; Jing Liu
Journal:  Int J Med Sci       Date:  2020-07-25       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.